These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24390981)
41. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822 [TBL] [Abstract][Full Text] [Related]
42. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Khoo NK; Chan FP; Saarloos MN; Lala PK Clin Exp Metastasis; 1992 Jul; 10(4):239-52. PubMed ID: 1617832 [TBL] [Abstract][Full Text] [Related]
43. Toll-like receptor 7 agonist induces hypoplasia of the biliary system in a neonatal mouse model. Huang YH; Shih HH; Tiao MM; Huang CC; Kuo KC; Huang FC; Yang YL; Chuang JH J Microbiol Immunol Infect; 2018 Apr; 51(2):166-173. PubMed ID: 27590984 [TBL] [Abstract][Full Text] [Related]
44. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects. Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376 [TBL] [Abstract][Full Text] [Related]
45. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567 [TBL] [Abstract][Full Text] [Related]
47. Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity. Ren S; Wang X; Jin G Int J Biol Sci; 2022; 18(1):166-179. PubMed ID: 34975325 [TBL] [Abstract][Full Text] [Related]
48. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878 [TBL] [Abstract][Full Text] [Related]
49. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation. Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685 [TBL] [Abstract][Full Text] [Related]
51. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173 [TBL] [Abstract][Full Text] [Related]
52. The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells. Wang C; Zhou Q; Wang X; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L Oncotarget; 2015 Jan; 6(3):1779-89. PubMed ID: 25593198 [TBL] [Abstract][Full Text] [Related]
53. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity. Biffen M; Matsui H; Edwards S; Leishman AJ; Eiho K; Holness E; Satterthwaite G; Doyle I; Wada H; Fraser NJ; Hawkins SL; Aoki M; Tomizawa H; Benjamin AD; Takaku H; McInally T; Murray CM Br J Pharmacol; 2012 May; 166(2):573-86. PubMed ID: 22122192 [TBL] [Abstract][Full Text] [Related]
54. Respiratory Influenza A Virus Infection Triggers Local and Systemic Natural Killer Cell Activation Stegemann-Koniszewski S; Behrens S; Boehme JD; Hochnadel I; Riese P; Guzmán CA; Kröger A; Schreiber J; Gunzer M; Bruder D Front Immunol; 2018; 9():245. PubMed ID: 29497422 [TBL] [Abstract][Full Text] [Related]
55. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Pilch Z; Tonecka K; Braniewska A; Sas Z; Skorzynski M; Boon L; Golab J; Meyaard L; Rygiel TP Cancer Immunol Res; 2018 Aug; 6(8):930-940. PubMed ID: 30021725 [TBL] [Abstract][Full Text] [Related]
56. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511 [TBL] [Abstract][Full Text] [Related]
57. Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model. Byun HK; Kim KJ; Han SC; Seong J Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1559-1569. PubMed ID: 33321193 [TBL] [Abstract][Full Text] [Related]
58. Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility. Nakamura T; Wada H; Kurebayashi H; McInally T; Bonnert R; Isobe Y Bioorg Med Chem Lett; 2013 Feb; 23(3):669-72. PubMed ID: 23265901 [TBL] [Abstract][Full Text] [Related]
59. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Lee AS; Ghoreishi M; Cheng WK; Chang TY; Zhang YQ; Dutz JP Diabetologia; 2011 Jun; 54(6):1407-16. PubMed ID: 21340621 [TBL] [Abstract][Full Text] [Related]
60. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]